CER-202

CER-202 is a chemical compound identified as a selective histamine H₃-receptor antagonist and inverse agonist. Developed by Laboratoires Servier, it was investigated for its potential therapeutic applications, particularly in the treatment of cognitive disorders.

Pharmacology

CER-202 primarily targets the histamine H₃ receptor (H₃R), a G protein-coupled receptor predominantly found in the central nervous system. The H₃R functions as both a presynaptic autoreceptor and a heteroreceptor. As an autoreceptor, it modulates the synthesis and release of histamine itself. As a heteroreceptor, it regulates the release of other important neurotransmitters, including acetylcholine, dopamine, norepinephrine, and serotonin.

By acting as an antagonist or inverse agonist, CER-202 blocks or reverses the constitutive activity of the H₃R. This action leads to an increase in the release of histamine and other neurotransmitters in various brain regions. The enhanced neurotransmitter release is hypothesized to improve various cognitive functions, such as alertness, attention, learning, and memory.

Potential Applications

CER-202 was primarily explored as a potential therapeutic agent for neurological and psychiatric conditions characterized by cognitive impairment. Specific areas of research and potential application included:

• Alzheimer's Disease: Due to its potential to enhance cholinergic transmission, which is often deficient in Alzheimer's disease.
• Schizophrenia: Investigated for its ability to ameliorate the cognitive deficits frequently associated with the disorder.
• Attention-Deficit/Hyperactivity Disorder (ADHD): Based on its potential to improve attention and focus by modulating neurotransmitter systems involved in these processes.

Development Status

The development of CER-202 appears to have been discontinued or significantly halted. While it showed promising preclinical results in various animal models and entered early clinical trials, it did not progress to become an approved medication for any indication. Publicly available information regarding its specific clinical trial outcomes beyond early phases is limited, and most research papers mentioning CER-202 date primarily from the early 2000s, suggesting that its active development period has passed.